Abstract

The pluripotent transcription factor NANOG is essential for maintaining embryonic stem cells and driving tumorigenesis. We previously showed that PKC activity is involved in the regulation of NANOG expression. To explore the possible involvement of microRNAs in regulating the expression of key pluripotency factors, we performed a genome-wide analysis of microRNA expression in the embryonal carcinoma cell line NT2/D1 in the presence of the PKC activator, PMA. We found that MIR630 was significantly upregulated in PMA-treated cells. Experimentally, we showed that transfection of MIR630 mimic into embryonal carcinoma cell lines directly targeted the 3′UTR of OCT4, SOX2, and NANOG and markedly suppressed their expression. RNAhybrid and RNA22 algorithms were used to predict miRNA target sites in the NANOG 3′UTR, four possible target sites of MIR630 were identified. To examine the functional interaction between MIR630 and NANOG mRNA, the predicted MIR630 target sites in the NANOG 3′UTR were deleted and the activity of the reporters were compared. After targeted mutation of the predicted MIR630 target sites, the MIR630 mimic inhibited NANOG significantly less than the wild-type reporters. It is worth noting that mutation of a single putative binding site in the 3′UTR of NANOG did not completely abolish MIR630-mediated suppression, suggesting that MIR630 in the NANOG 3′UTR may have multiple binding sites and act together to maximally repress NANOG expression. Interestingly, MIR630 mimics significantly downregulated NANOG gene transcription. Exogenous expression of OCT4, SOX2, and NANOG lacking the 3′UTR almost completely rescued the reduced transcriptional activity of MIR630. MIR630 mediated the expression of differentiation markers in NT2/D1 cells, suggesting that MIR630 leads to the differentiation of NT2/D1 cell. Our findings show that MIR630 represses NANOG through transcriptional and post-transcriptional regulation, suggesting a direct link between core pluripotency factors and MIR630.

Highlights

  • We previously reported that Protein Kinase C (PKC) activity is involved in the regulation of NANOG expression [13]

  • We explored the possible involvement of miRNAs in PKC activation-induced downregulation of NANOG

  • We performed a genome-wide analysis of miRNA expression in NT2/D1 cells in the presence of PKC activator, phorbol 12-myristate 13-acetate (PMA), in an attempt to link this change to altered NANOG expression

Read more

Summary

Introduction

A number of transcription factors have been shown to play critical roles in the selfrenewal and maintenance of pluripotency in embryonic stem cell (ESCs), among them. Cancer cells and ESCs have been shown to share many key biological properties, including high proliferative potential, which is essential for embryogenesis and tumor development. We showed that by inhibiting PKC activity, NANOG expression was upregulated in six human cancer cell lines. In constitutively NANOG-overexpressing human embryonal carcinoma cells (NT2/D1 and NCCIT), NANOG expression was repressed by PKC activation. Ectopic PKCα expression in NT2/D1 cells suppressed the expression of NANOG and TRA-1-60, a human pluripotent stem cell marker. Since NANOG expression appears to play a regulatory role in tumor growth, we suggest that the PKC-NANOG pathway may be involved in tumor development and progression

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call